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Abstract: Chronic, noncancer pain such as that associated with osteoarthritis of the hip and 
knee is typically managed according to American College of Rheumatology guidelines. Patients 
unresponsive to ﬁ  rst-line treatment with acetaminophen receive nonsteroidal antiinﬂ  ammatory 
drugs (NSAIDs), including cyclooxygenase-2 (COX-2) inhibitors. However, many patients may 
have chronic pain that is refractory to these agents, or they may be at risk for the gastrointestinal, 
renal, and cardiovascular complications associated with their use. Tramadol, a mild opioid ago-
nist and norepinephrine and serotonin reuptake inhibitor, is recommended by current guidelines 
for the treatment of moderate to moderately severe pain in patients who have not responded 
to previous oral therapy, or in patients who have contraindications to COX-2 inhibitors and 
nonselective NSAIDs. An extended-release (ER) formulation of tramadol was approved by the 
US Food and Drug Administration in September 2005. In contrast with immediate-release (IR) 
tramadol, this ER formulation allows once-daily dosing, providing around-the-clock analgesia. 
In clinical studies, tramadol ER has demonstrated a lower incidence of adverse events than that 
reported for IR tramadol. Unlike nonselective NSAIDs and COX-2 inhibitors, tramadol ER is 
not associated with gastrointestinal, renal, or cardiovascular complications. Although tramadol 
is an opioid agonist, signiﬁ  cant abuse has not been demonstrated after long-term therapy. It 
is concluded that tramadol ER has an efﬁ  cacy and safety proﬁ  le that warrants its early use for 
the management of chronic pain, either alone or in conjunction with nonselective NSAIDs and 
COX-2 inhibitors.
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Introduction 
Chronic pain was originally deﬁ  ned as pain lasting 3–6 months after onset, but has 
since been described as pain that extends beyond the healing period, disrupts sleep or 
normal activities, and is not explained by the low levels of pathology that characterize 
the disease or condition (JCAHO 2001).
Patients with lower back pain, myofascial pain, and osteoarthritis (OA) are the 
most likely to suffer from chronic pain, which is one of the leading causes of dis-
ability within the work force (Yelin and Callahan 1995; CDC 2001; APF 2002). Over 
40% of patients with musculoskeletal disease reported some form of disability, and 
more than half of working age people with musculoskeletal conditions were unable 
to work (Yelin and Callahan 1995; CDC 2001). According to the American College 
of Rheumatologists (ACR), 21 million Americans are affected by OA, which is as-
sociated with annual losses of 36 million workdays (Babul et al 2004; ACR 2005). 
The impact of chronic pain may be even greater; recent estimates by the Center for 
Disease Control place the number of adults with arthritis and chronic joint symptoms 
at around 70 million (CDC 2002).Therapeutics and Clinical Risk Management 2007:3(3) 402
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Living with chronic pain signiﬁ  cantly reduces patients’ 
quality of life. In a study of 306 patients aged 55–74 years, 
patients with chronic pain in the hip or knee reported a 
signiﬁ  cantly lower quality of life than a reference group 
not suffering from chronic pain (p < 0.045) (Hopman-Rock 
et al 1997). As outlined in Table 1, untreated pain increases 
anxiety and depression, and is commonly associated with a 
decreased ability to cope (Eisendrath 1995; Yelin and Cal-
lahan 1995; APS 1996; Cohen et al 2000).
The effects of chronic pain on patients’ quality of life are 
also reﬂ  ected in the low degree of life satisfaction in patients 
with this condition (Laborde and Powers 1980). According 
to the American Pain Foundation, two thirds of chronic pain 
sufferers were unable to perform routine physical tasks or 
to enjoy their hobbies, even though they were taking pain 
medication (APF 2006). The impact of chronic pain is under-
scored by the ﬁ  nding that past, present, and future satisfaction 
scores (assessed on Cantril’s self-anchoring scale) showed 
that patients with severe OA had signiﬁ  cantly lower life 
satisfaction scores than patients on hemodialysis (p < 0.05) 
(Laborde and Powers 1980). 
Sleep disturbance is another major concern of patients 
with noncancer chronic pain; poor sleep has been reported 
in 70% of patients in chronic pain clinics and in 60% of pa-
tients suffering from arthritis (Menefee, Cohen, et al 2000). 
A cross-sectional survey of 167 patients with chronic spinal 
pain showed that high sleep quality and low sleep latency 
correlated positively with a shorter duration of pain and 
improved physical functioning (Menefee, Frank, et al 2000). 
High pain scores were independent indicators of overall 
sleep quality and sleep latency (Menefee, Frank, et al 2000). 
A small comparative study between 16 healthy subjects 
and 14 patients with OA showed an association between 
chronic pain and changes in EEG sleep patterns (Leigh et al 
1988). Signiﬁ  cant increases in stage I sleep (drowsiness), 
accompanied by decreases in stage II sleep (sleep onset), 
were observed in patients with OA, compared with normal 
subjects (Leigh et al 1988).
Chronic pain is also associated with considerable eco-
nomic costs. In the US in 2002, total lost productivity costs 
due to arthritis and lower back pain were estimated at US 
$10.3 billion and $19.8 billion, respectively (Stewart et al 
2003).
Treatment guidelines for management 
of chronic pain
For patients with OA of the hip and knee, chronic pain is 
typically managed according to ACR guidelines, as outlined 
in Figure 1 (ACR 2000). Acetaminophen is recommended 
as ﬁ  rst-line therapy, although even doses up to 4 g may not 
provide sufﬁ  cient pain relief (ACR 2000). Nonselective 
NSAIDs and COX-2 inhibitors are recommended for patients 
intolerant or unresponsive to acetaminophen (ACR 2000). 
The decision to prescribe nonselective NSAIDs is largely 
determined by a patient’s risk for upper gastrointestinal 
(GI) disorders following treatment with these agents. These 
include a history of peptic ulcer disease, increased GI bleed-
ing, use of corticosteroids or anticoagulants (ACR 2000), 
and generally poor state of health (ACR 2000). Nonselective 
NSAIDs and COX-2 inhibitors can cause renal toxicity and 
should be used with caution in patients with mild to moderate 
renal insufﬁ  ciency; these agents should not be used in patients 
with severe renal insufﬁ  ciency (ACR 2000). Nonselective 
NSAIDs in combination with gastroprotective agents – miso-
prostol or a proton pump inhibitor – are recommended for 
patients unable to take either COX-2 inhibitors or nonselec-
tive NSAID monotherapy (ACR 2000). Patients susceptible 
to NSAID-induced platelet inhibition and bleeding may be 
prescribed nonacetylated salicylates (ACR 2000).
Tramadol is a centrally acting oral analgesic that blocks 
pain through opioid receptor binding and inhibition of nor-
epinephrine and serotonin reuptake. It is currently indicated 
for the management of moderate to moderately severe pain 
in adults (Ultram PI 2004). Tramadol may be combined with 
NSAIDs in patients whose symptoms are poorly controlled by 
these agents (ACR 2000). Immediate-release (IR) tramadol 
is initiated at 25 mg and titrated in 25 mg increments over 
3 days to achieve 25 mg four times daily (qid), then in 50 mg 
increments over 3 days to 50 mg qid (Ultram PI 2004). After 
titration, tramadol may be administered in doses of 50 mg 
Table 1 Morbidity associated with untreated chronic pain (APS 
1996)
Decreased quality of life 
Sleep disturbance 
Adverse impact on:
Concentration
Ability to work
Ability to exercise
Physical function
Cognitive functions
Daily living
Social relationships
Depression
Increased anxiety
Inability to copeTherapeutics and Clinical Risk Management 2007:3(3) 403
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to 100 mg every 4–6 hours as required for pain relief up to 
a daily maximum of 400 mg; the mean effective daily dos-
age is between 100 mg and 300 mg (Ultram PI 2004). The 
most common side effects of tramadol are dizziness, nausea, 
constipation, and drowsiness (Ultram PI 2004). Despite its 
mild opioid effects, tramadol has a low potential for abuse 
and remains the only unscheduled opioid (ACR 2000).
More potent opioid therapy is recommended for patients 
unresponsive to or intolerant of tramadol (ACR 2000). Joint 
guidelines have been published by the American Pain Society 
and American Academy of Pain Medicine on the use of more 
potent opioids for the management of chronic, noncancer 
pain. Lifesaving and safe for many patients, a cautious ap-
proach with a careful risk assessment should be done in all 
patients taking opioids (ACR 2000).
Limitations associated with chronic pain 
treatment
Despite the presence of established treatment guidelines, 
chronic pain remains an undertreated condition (Weinstein 
et al 2000; Glajchen 2001). Almost half of all patients in rou-
tine clinical practice experience inadequate relief from chronic 
pain (Cherny and Portenoy 1994; Glajchen 2001). Low patient 
satisfaction with analgesic therapy is further evidenced by the 
fact that Americans over age 60 years consult at least 3 physi-
cians about their pain medications (APF 2006).
There are a variety of factors leading to the low effec-
tiveness of chronic pain therapy, including patient factors, 
physician education, regulatory oversight, and formulary 
issues. The relatively low effectiveness of chronic pain 
therapy may be related to various limitations of currently 
used analgesics (Table 2), as well as conservative dosing by 
physicians (ACR 2000; Weinstein et al 2000; Stephens et al 
2003; Hudson et al 2005; Caldwell et al 2006). Treatment 
with NSAIDs is restricted by their association with increased 
risk for GI side effects, renal toxicity, and cardiovascular 
toxicity, especially in the elderly (ACR 2000). Risk factors 
for reversible renal failure in patients with intrinsic renal 
disease receiving nonselective NSAIDs include age (≥65 
years), hypertension, and congestive heart failure (Page and 
Henry 2000). Studies have shown that subjects with a history 
of heart disease receiving nonselective NSAIDs had a 10.5-
fold increased risk for congestive heart failure, compared 
with non-NSAID users (Page and Henry 2000).
Recent studies have shown that COX-2 inhibitors are 
similarly associated with cardiovascular safety issues. Using 
published and unpublished data between 1966 and 2005, a 
meta-analysis of randomized comparative trials of at least 
4 weeks’ duration showed both selective COX-2 inhibitors 
and certain high-dose nonselective NSAIDs signiﬁ  cantly 
increased the risk for cardiovascular events (Kearney et al 
2006). Compared with placebo, COX-2 inhibitors showed 
a relative increase of 42% in serious vascular events 
(p = 0.003), which was similar to that found with certain 
nonselective NSAIDs. (Kearney et al 2006).
Table 2 Limitations of pharmacologic therapy for chronic pain
Therapeutic class  Major limitations
Nonselective NSAIDs   Risk for gastrointestinal toxicitya
  Recommended use of concomi 
  tant gastroprotective agents 
 increases  costa
  Risk for renal toxicitya
  Cardiovascular safety issuesb
COX-2 Inhibitors  Increased risk 
  Cardiovascular safety issuesc 
 Renal  toxicitya 
Opioids Associated  with:
  Reduced cognitive and motor  
 functiond
 Respiratory  depressione
  Fear of dependence/tolerance/ 
 abusef
  Stringent regulatory requirements   
  and potential for scrutiny may  
  limit adequate prescribingf
Notes: aACR 2000; bHudson et al. 2005; cCaldwell et al. 2006; dJCAHO 2001; 
eStephens et al. 2003; fWeinstein et al. 2000. 
Abbreviations: COX-2, cyclooxygenase-2; NSAIDs, nonsteroidal antiinﬂ  ammatory 
drugs.
Acetaminophen
Gastrointestinal and
Renal Risk Assessment
COX-2 Inhibitors or
Nonselective NSAIDs ± gastroprotective agents or
Non-acetylated salicylates
Strong opioids ± acetaminophen
Tramadol
Figure 1 ACR treatment guidelines for pharmacological management of noncancer 
chronic pain systemic agents (ACR 2000).
Abbreviations: ACR, American College of Rheumatology; COX-2, cyclooxygen-
ase-2; NSAIDs, nonsteroidal antiinﬂ  ammatory drugs.Therapeutics and Clinical Risk Management 2007:3(3) 404
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Formulation, pharmacokinetics, and 
mechanism of action of tramadol ER
Formulation 
Tramadol ER is an ER formulation of (±) cis-2-
[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexa-
nol hydrochloride combined with ethyl cellulose, dibutyl 
sebacate, polyvinylpyrrolidone, sodium stearyl fumarate, 
colloidal silicon dioxide, and polyvinyl alcohol (Figure 2) 
(Ultram ER PI 2006). Tramadol ER was recently approved 
as a nonscheduled analgesic for the control of moderate to 
moderately severe pain in adults who require treatment over 
an extended time period (Ultram ER PI 2006).
Pharmacokinetics 
Orally administered tramadol ER 100 mg to 400 mg exhib-
ited dose-proportional pharmacokinetics in healthy human 
volunteers (Ultram ER PI 2006). Tramadol ER is extensively 
metabolized through multiple cytochrome P450 pathways 
(3A4, 2B6, 2D6), of which 2D6 is responsible for forma-
tion of the O-demethylated metabolite, M1 (Ultram ER PI 
2006). The analgesic activity of tramadol ER is mediated 
by racemic forms of both tramadol and M1 (Ultram ER 
PI 2006). However, tramadol has up to a six-fold greater 
analgesic effect than the M1 metabolite in animal models 
(Ultram ER PI 2006).
Tramadol ER 200 mg once daily (qd) was compared with 
tramadol IR 50 mg every six hours (q6h) in healthy subjects. 
Tramadol ER showed a steady and sustained rise in plasma 
concentration during the 24-hour period after administration, 
compared with tramadol IR, which exhibited more frequent 
ﬂ  uctuations (Figure 3) (Ultram ER PI 2006). The M1 me-
tabolite exhibited a pharmacokinetic proﬁ  le similar to that 
of the parent drug (Ultram ER PI 2006). Tramadol and its 
M1 metabolite attained mean peak plasma concentrations 
at 12–15 hours, reaching steady state at 4 days (Ultram ER 
PI 2006).
Tramadol ER may be taken without food. A high-fat meal 
slightly decreased tramadol area under the curve (AUC) and 
maximum concentration (Cmax) 16% and 28%, respectively, 
and extended its half-life to 17 hours, compared with 14 hours 
in fasted conditions (Ultram ER PI 2006).
Mechanism of action 
The analgesic efﬁ  cacy of tramadol and its M1 metabolite has 
been established in various rodent models of pain (Hennies 
et al 1988; Kayser et al 1991; Raffa et al 1992, 1995; Mattia 
et al 1993).
Competitive binding to rodent brain membranes in vitro 
showed that tramadol is a selective µ-opioid receptor agonist 
with a 200-fold lower afﬁ  nity for µ-opioid receptors than its 
M1 metabolite (Hennies et al 1988; Raffa et al 1995). Opioid 
agonist activity appeared to be mediated by the dextrorotatory 
(+) enantiomeric form of tramadol, as opposed to the mirror 
image levorotatory (–) form (Raffa et al 1995). Tramadol is 
a relatively weak µ-opioid agonist; its afﬁ  nity for µ-opioid 
receptors was 6000, 60, and 10 tmes lower than that of 
morphine, dextropropoxyphene, and codeine, respectively 
(Raffa et al 1995). Tramadol’s µ-opioid receptor binding and 
analgesic effects were only partially blocked by naloxone, 
suggesting other nonopioid mechanisms of analgesia (Hen-
nies et al 1988; Raffa et al 1992).
In vitro studies, using rodent synaptosomes, showed that 
tramadol was more potent with respect to norepinephrine and 
serotonin reuptake inhibition than µ-opioid receptor binding 
(Hennies et al 1982; Raffa et al 1992). That tramadol medi-
ated its analgesic effects through inhibition of monoamine 
Figure 2 Structure of tramadol extended-release: (±) cis-2-[(dimethylamino) 
methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride (Ultram PI 2004).
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Figure 3 Pharmacokinetics of tramadol ER 200 mg once daily (qd) versus tramadol 
IR 50 mg every 6 hours (q6h) (mean steady-state tramadol plasma concentrations 
in healthy subjects on day 8 post dose) (Ultram PI 2006).
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reuptake in vivo was conﬁ  rmed in animal and human stud-
ies, in which tramadol’s analgesic effects were blocked by 
yohimbine (Raffa et al 1992; Desmeules et al 1996).
Intrathecal tramadol produced a weak analgesic effect 
in mice (Mattia et al 1993). In contrast, administration of 
tramadol by the intracerebroventricular route followed by in-
trathecal injection resulted in powerful synergistic analgesia, 
implicating both the brain and spinal cord as the principal 
sites of action (Mattia et al 1993). Unlike other centrally act-
ing analgesics, tramadol demonstrated limited potential for 
tolerance in mouse and rat pain models (Kayser et al 1991; 
Mattia et al 1993).
Efﬁ  cacy 
Effectiveness in clinical practice and clinical trials is the 
standard by which the true potential of a drug is determined. 
Tramadol IR has been widely prescribed as an unscheduled 
opioid in the US for the treatment of chronic pain for more 
than 10 years, and has demonstrated efﬁ  cacy and safety in 
the treatment of moderate to moderately severe pain (ACR 
2000; Ultram PI 2004; Mattia and Coluzzi 2005). Although 
tramadol has opioid analgesic effects, signiﬁ  cant abuse has 
not been demonstrated after long-term therapy (ACR 2000; 
Cicero, Inciardi, Adams, et al 2005).
Effect on pain measures
The analgesic effects of tramadol ER were initially explored 
in patients with moderate to moderately severe chronic pain 
due to osteoarthritis and/or low back pain in 12-week, ran-
domized, double-blind, placebo-controlled trials (Ultram ER 
PI 2006). Moderate to moderately severe pain was deﬁ  ned by 
a pain intensity score of   40 mm, off previous medications, 
on a 0 to 100 mm visual analog scale (VAS). 
In one of these studies, patients with moderate to 
moderately severe pain due to OA of the knee and/or hip 
received tramadol ER 100 mg to 400 mg daily (Ultram PI 
2006). Treatment was initiated at 100 mg for 4 days, and 
then increased every 5 days by 100 mg increments up to 
400 mg. Pain was measured by the the Western Ontario and 
McMaster Universities (WOMAC) Pain subscale. Change 
in baseline pain was assessed at 1, 2, 3, 6, 9, and 12 weeks 
after treatment.
A responder analysis, based on the percent change in 
the WOMAC Pain subscale, demonstrated a statistically 
signiﬁ  cant improvement in pain for the 100 mg and 200 mg 
treatment groups, compared with placebo (Figure 4) (Ultram 
PI 2006). Surprisingly, the proportion of patients achieving 
improvement in pain with tramadol ER 300 mg and 400 mg 
was not signiﬁ  cantly different from placebo. A 12-week, 
randomized, double-blind, placebo-controlled, ﬂ  exible-dose 
study of patients with OA f the knee showed improvement 
in pain based on the Arthritis Pain Intensity VAS (Ultram PI 
2006). Signiﬁ  cant improvement was observed with a trama-
dol ER mean daily dose of 270 mg (Ultram PI 2006).
The analgesic efﬁ  cacy of tramadol ER was also examined 
in a 12-week, randomized, double-blind, placebo-controlled, 
Response Threshold (Percent Improvement from Baseline)
P
e
r
c
e
n
t
o
f
 
P
a
t
i
e
n
t
s
A
c
h
i
e
v
i
n
g
 
R
e
s
p
o
n
s
e
Tramadol ER 100 mg
Tramadol ER 200 mg
Tramadol ER 300 mg
Tramadol ER 400 mg
Placebo
01 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 100
0
10
20
30
40
50
60
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ﬂ  exible-dose study of 246 patients with osteoarthritis of the 
knee and moderate to severe chronic pain (Babul et al 2004). 
Patients with a mean age of 61 years and average disease 
duration of 12–13 years were randomized to tramadol ER 
(n = 124) or placebo (n = 122) (Babul et al 2004). Tramadol 
ER 100 mg was administered once daily for the ﬁ  rst 4–8 
days according to treatment tolerability and then increased 
to 200 mg (Babul et al 2004). Further titrations up to 300 
mg or 400 mg were allowed based on analgesic efﬁ  cacy and 
tolerability (Babul et al 2004). The mean tramadol ER dose 
was 276 mg, close to the highest recommended daily dose 
of 300 mg (Babul et al 2004; Ultram PI 2006).
Analgesic efﬁ  cacy was assessed as reduction of pain from 
baseline through 12 weeks using the Arthritis Pain Intensity 
VAS (Figure 5) (Babul et al 2004). After 1 week of treat-
ment, VAS scores were decreased by 25% for tramadol ER 
compared with 14% for placebo (Babul et al 2004). Improve-
ments in pain scores increased over time and were sustained 
up to 12 weeks; the mean change in VAS from baseline to 
12 weeks was signiﬁ  cantly greater for tramadol ER (49%) 
than placebo (27%; p < 0.001) (Babul et al 2004). It should 
be noted that the placebo response rate of 27% is not uncom-
mon in analgesia trials (Turner et al 1994).
WOMAC OA subscales were evaluated as a further 
measure of pain, stiffness, and physical function (Figure 6) 
(Babul et al 2004). As with the Arthritis Pain Intensity VAS, 
the WOMAC pain subscale improved signiﬁ  cantly from 
baseline over the 12-week period following treatment with 
tramadol ER (Babul et al 2004). Tramadol ER signiﬁ  cantly 
improved the mean WOMAC pain score from baseline by 
45% compared with 25% for placebo (p < 0.001); an ef-
fect consistent with changes observed in the Arthritis Pain 
Intensity VAS (Babul et al 2004). Similar improvements in 
the WOMAC stiffness and physical function scores were 
observed following 12 weeks of tramadol ER therapy. Stiff-
ness and physical function scores were increased by 43% and 
44% for tramadol ER compared with 18% and 21% in the 
placebo group (p < 0.001) (Babul et al 2004).
Patient Global Assessment and Physician Global Assess-
ment of pain were signiﬁ  cantly better for tramadol ER than 
placebo from baseline to 12 weeks of therapy (p < 0.001) 
(Babul et al 2004). Treatment discontinuation was signiﬁ  -
cantly lower with tramadol ER (19%) than placebo (38%; 
p < 0.001) (Babul et al 2004).
Effect of pain management on sleep
Since sleep disturbances are common in patients with chronic 
pain, the Chronic Pain Sleep Inventory was used to evaluate 
the effect of chronic pain management on sleep in this study 
(Menefee, Cohen, et al 2000; Babul et al 2004). Pain relief with 
tramadol ER was associated with improvements in sleep from 
baseline, compared with placebo, that were statistically signiﬁ  -
cant from week 2 to week 12 (p < 0.05 vs placebo) (Babul et al 
2004). Improvements were noted in speciﬁ  c pain-related sleep 
parameters: being awakened by pain, trouble falling asleep due 
to pain, and overall quality of sleep (Babul et al 2004).
Safety
The safety of tramadol ER has been established in several 
double-blind studies of patients with OA or chronic low 
Figure 5 Efﬁ  cacy of tramadol ER in patients with osteoarthritis: mean change from baseline in Arthritis Pain Intensity VAS assessed through 12 weeks.  Reprinted from 
Babul N, Noveck R, Chipman H, et al. 2004. Efﬁ  cacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis 
of the knee. J Pain Symptom Management, 28:59–71. Copyright © 2004 with permission from Elsevier. 
Abbreviations: ER, extended release; VAS, Visual Analogue Scale.
0
10
20
30
40
50
60
1248 1 2
Weeks
Tramadol ER Placebo (n = 122)
M
e
a
n
p
e
r
c
e
n
t
 
i
m
p
r
o
v
e
m
e
n
t
f
r
o
m
b
a
s
e
l
i
n
e
i
n
a
r
t
h
r
i
t
i
s
p
a
i
n
i
n
t
e
n
s
i
t
y
(
V
A
S
)
*
*
*
* *
* p < 0.003 vs placebo
(n = 124)Therapeutics and Clinical Risk Management 2007:3(3) 407
Tramadol ER in the management of chronic pain
back pain, or both and one open-label study in patients 
with chronic noncancer pain conducted within the US 
(Ultram PI 2006). These studies included a total of 3108 
patients, of whom 901 were at least 65 years of age (Ultram 
PI 2006).
In two 12-week, randomized, double-blind, placebo-
controlled studies of patients with chronic non-cancer pain, 
adverse events increased with dose from 100 mg to 400 mg 
(Ultram PI 2006). The most frequently reported adverse 
events for tramadol ER 100 to 400 mg ranged from 16% 
to 28% (dizziness), 15% to 26% (nausea), and 12% to 30% 
(constipation) (Ultram PI 2006). A lower incidence of these 
adverse events was observed in the placebo group, ranging 
from 4% to 8% (Ultram PI 2006).
In the 12-week study of 246 patients with OA recently 
reported by Babul and colleagues (2004), the overall inci-
dence of adverse events over the study period was higher 
for patients receiving tramadol ER compared with placebo 
(79.0% vs 63.9%; p = 0.011). Adverse events possibly 
related to treatment were reported for 63.7% and 32% of 
patients in the tramadol ER and placebo groups, respec-
tively (p < 0.001) (Babul et al 2004). More than 90% of 
the adverse events in both treatment groups were of mild or 
moderate severity (Babul et al 2004). The most frequently 
reported adverse events in the tramadol ER group were 
dizziness (33%), constipation (26%), and nausea (24%) 
(Babul et al 2004). In contrast, the incidence of these 
adverse events was lower in the placebo group, ranging 
from 6% to 12% (Babul et al 2004). Although tramadol 
ER treatment in this study was initiated at a daily dose of 
100 mg, certain patients received dose increases up to 400 
mg based on the adequacy of pain relief and tolerability of 
side effects. Therefore, the 400 mg dose of tramadol ER, 
which is not approved for treatment of chronic pain, may 
have contributed to the higher rate of adverse events in this 
study (Ultram PI 2006).
Unlike other agents such as nonselective NSAIDs and 
COX-2 inhibitors, tramadol has no known association with 
cardiovascular disease or stomach ulcers.
Tramadol ER should be used with caution in the geriatric 
population (Tramadol ER PI 2006). A study of 901 patients 
at least 65 years of age showed that the incidence of adverse 
events was highest in the group over 75 years of age receiv-
ing tramadol ER (Tramadol PI 2006).
Like other opioids, tramadol ER is contraindicated in 
states of acute intoxication with alcohol, narcotics, hypnotics, 
centrally acting analgesics, opioids, or psychotropic agents 
(Ultram PI 2006).
Tramadol ER use may be limited by its potential to in-
crease risk of seizures (Ultram PI 2006). Seizures have been 
reported in patients taking tramadol within the recommended 
dose range (Ultram PI 2006). Tramadol increased the risk 
for seizure in patients taking serotonin reuptake inhibitors, 
tricyclic antidepressants, and opioids (Ultram PI 2006). Tra-
madol ER may also increase the risk for seizure if combined 
with drugs that decrease seizure threshold, such as mono-
amine oxidase inhibitors (Ultram PI 2006). Furthermore, 
combination of tramadol ER with central nervous system 
Figure 6 Efﬁ  cacy of tramadol ER in patients with osteoarthritis using the WOMAC pain, stiffness, and physical function subscales. Mean percentage change in subscales 
were assessed from baseline to 12 weeks of treatment. Tramadol ER signiﬁ  cantly improved pain, stiffness, and physical function subscales, compared with placebo (p < 0.001). 
Reprinted from Babul N, Noveck R, Chipman H, et al. 2004. Efﬁ  cacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial 
in osteoarthritis of the knee. J Pain Symptom Management, 28:59–71. Copyright © 2004 with permission from Elsevier. 
Abbreviations: ER, extended release;   WOMAC, Western Ontario and McMaster Universities.
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(CNS) depressants may produce respiratory depression, a 
reported side effect of opioid therapy (Stephens et al 2003; 
Ultram PI 2006). 
Use of tramadol ER may be limited in patients with 
renal or hepatic impairment (Ultram PI 2006). Following 
repeated doses of tramadol ER 100 mg, exposure of the 
tramadol M1 metabolite was increased by 20%–40% in 
patients with mild (creatinine clearance = 50–80 mL/min) 
or moderate (creatinine clearance = 30–50 mL/min) renal 
impairment, compared with normal subjects (Ultram PI 
2006). Additionally, exposure of the M1 metabolite was 
decreased by approximately 50% in patients with mild 
and moderate hepatic impairment, compared with normal 
subjects (Ultram PI 2006). It is recommended that tramadol 
ER should not be used in patients with severe renal impair-
ment (creatinine clearance <30 mL/min) or severe hepatic 
impairment (Ultram PI 2006).
Tramadol ER vs tramadol IR 
Data from separate studies of tramadol IR and tramadol ER 
(90 days’ and 12 weeks’ duration, respectively) suggest 
that tramadol ER has a lower propensity for adverse events 
than tramadol IR (Ultram PI 2004; Ultram ER PI 2006). 
The most frequently reported adverse events for tramadol 
IR and tramadol ER were in the CNS and the GI system 
(Ultram PI 2004; Ultram ER PI 2006). Adverse event rates 
– occurring with an incidence of at least 5% – were higher 
with tramadol IR than tramadol ER (reported above); event 
rates for constipation, nausea, and dizziness were 46%, 40%, 
and 33%, respectively, after 90 days of tramadol IR therapy 
(Ultram PI 2004; Ultram ER PI 2006).
Like tramadol IR, tramadol ER has the potential for 
interacting with 2D6- and 3A4- inhibitors that may alter 
tramadol’s efﬁ  cacy by lowering M1 metabolite levels or 
changing tramadol’s exposure (Ultram PI 2006). Metabolism 
of tramadol ER may also be compromised in patients with 
2D6 gene dysfunction, which is present in approximately 
8%–10% of the Caucasian population, reducing its analgesic 
efﬁ  cacy (Gough et al 1990; Garcia-Quetglas et al 2007).
NSAID dose-sparing potential of tramadol
Combination of tramadol with NSAIDs for the management 
of chronic pain has the potential to reduce NSAID require-
ments. In a randomized, double-blind, placebo-controlled 
study with tramadol IR in patients with OA, in those patients 
who responded to naproxen, use of tramadol decreased the 
requirement for naproxen without compromising analgesic 
efﬁ  cacy (Schnitzer et al 1999).
Tramadol ER abuse
Tramadol appears to be associated with low rates of abuse 
(ACR 2000; Cicero, Inciardi, Adams, et al 2005). A phar-
macoepidemiologic surveillance study, conducted between 
1994 and 2004 among 309 drug abuse experts and 100 police 
agencies, reported that the rate of tramadol abuse was very 
low, ranging from 0.5 to 2.0 cases per 100,000 patients over 
the 10-year study period (Cicero, Inciardi, Adams, et al 
2005). Introduction of new branded and cheaper generic 
formulations in 2002 had no effect on the rate of tramadol 
abuse (Cicero, Inciardi, Adams, et al 2005). In contrast, the 
Research Abuse, Diversion, and Addiction-Related Surveil-
lance (RADARS) system showed abuse rates for controlled-
release oxycodone of at least 5 cases per 100,000 patients 
between 2002 and 2004 (Cicero, Inciardi, Munoz, et al 2005). 
Nevertheless, because tramadol exerts its analgesic effects 
in part through opioid binding, its potential for abuse should 
always be considered when prescribed for the treatment of 
chronic pain.
Optimizing therapy for chronic pain
The goals of managing chronic pain and improving patient 
quality of life can be achieved by optimizing analgesic 
therapy. The ideal treatment would be a once-daily formula-
tion with minimum side effects, around-the-clock pain relief, 
and no potential for end-organ injury. 
Of the currently recommended therapies, NSAIDs, 
including COX-2 inhibitors, may be undesirable choices 
for long-term treatment due to their potential for end-organ 
injury. In spite of the proven analgesic efﬁ  cacy of sched-
uled opioids, side effects and the need for risk assessment 
makes prescribing of these agents problematic for a busy 
provider (Cherny et al 1994; Parrott 1999; Weinstein et al 
2000; JCAHO 2001; Stephens et al 2003). In contrast to pure 
opioid analgesics, tramadol is an unscheduled partial opioid 
analgesic with a lower potential for tolerance and abuse (ACR 
2000; Cicero, Inciardi, Adams, et al 2005). However, because 
of the short half-life of tramadol IR, daily doses of 50 mg 
qid are required for maximum effect (Ultram PI 2004). Such 
a multiple-dose regimen results in frequent daily peak-to-
trough ﬂ  uctuations in plasma drug that may provide less than 
optimal analgesic activity, especially during the nighttime 
hours (Ultram PI 2006).
Tramadol ER represents a signiﬁ  cant advance over tra-
madol IR. Once-daily administration of tramadol ER allows 
for consistent sustained plasma drug levels over a 24-hour 
time period, providing around-the-clock analgesic effective-
ness (Ultram PI 2006). In this respect, tramadol ER has the Therapeutics and Clinical Risk Management 2007:3(3) 409
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potential to minimize sleep disturbances, an advantage that 
could translate into improved patient function and quality 
of life. Twenty-four hour pain relief could provide added 
beneﬁ  ts by reducing the overall pill burden and the need for 
sedatives and hypnotic agents to control sleep disturbance. 
These effects, combined with a lower incidence of adverse 
events, suggest tramadol ER would be better tolerated than 
tramadol IR and offer the potential for increasing patient 
compliance. 
Conclusions 
Current ACR treatment guidelines for chronic pain consist 
of a multistage treatment algorithm based on increasing 
analgesic potency. Tramadol is currently recommended as 
an alternative for patients unresponsive to or intolerant of 
nonselective NSAIDs and COX-2 inhibitors for the relief of 
moderate to severe chronic pain (ACR 2000). Tramadol ER 
has beneﬁ  ts that may merit its use earlier in the treatment 
decision process for moderate to moderately severe chronic 
pain. Tramadol ER, either as monotherapy or in combination 
with antiinﬂ  ammatory agents, as ﬁ  rst prescription therapy 
(following initial use of acetaminophen), for patients who 
require 24-hour relief from their moderate chronic pain may 
spare the use of nonselective NSAIDs and COX-2 inhibitors, 
as well as reduce side effects and improve patient compli-
ance. Tramadol ER may also postpone the need for scheduled 
opioids and the risks inherent in their use.
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